Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Altimmune ( (ALT) ) is now available.
On November 6, 2025, Altimmune, Inc. entered into a new Equity Distribution Agreement with Leerink Partners LLC for an at-the-market offering program, allowing the company to sell up to $200 million in common stock. This agreement follows the termination of a previous agreement from February 2025, which had a $150 million cap, and highlights Altimmune’s strategic move to potentially increase its capital through a more flexible sales arrangement, impacting its financial operations and stakeholder interests.
The most recent analyst rating on (ALT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score is primarily influenced by its financial challenges and valuation concerns, which are offset to some extent by positive developments in clinical trials and a strong cash position as highlighted in the earnings call. The technical analysis suggests a neutral market stance, providing neither strong bullish nor bearish signals.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Altimmune, Inc. operates in the biotechnology industry, focusing on the development of immunotherapeutic products. The company primarily works on vaccines, immune-modulating therapies, and treatments for liver disease, with a market focus on innovative health solutions.
Average Trading Volume: 2,777,525
Technical Sentiment Signal: Sell
Current Market Cap: $331.8M
For a thorough assessment of ALT stock, go to TipRanks’ Stock Analysis page.